From small molecules to peptides, proteins, oligonucleotides and vaccines — cyclodextrins are doing far more than just improving solubility.
In this practical webinar, we’ll look at: where cyclodextrins really add value; what commonly goes wrong; when CDs can move beyond excipients and become APIs; how to evaluate suppliers, CDMOs and development partners; emerging opportunities across pharma and biotech.
Expect real case studies, commercial examples, industry trends and plenty of practical takeaways for R&D, BD and commercial teams. And bring your own questions and use cases — this will be an interactive session.
👉 Register now and join the Cyclodextrin Masterclass.
Heading to CPHI? Continue the conversation with us at CarboHyde booth 8S83.
his webinar will explore the role of cyclodextrins in the formulation and delivery of small molecules, peptides, proteins and oligonucleotides, as well as their growing applications in vaccines and biotechnology.
We will also look beyond their traditional use as excipients and discuss cases where cyclodextrins themselves act as active pharmaceutical ingredients, including the commercial success of Sugammadex.
Through real-world case studies and commercial examples, we will highlight what works, what frequently goes wrong, and where cyclodextrin technologies can create meaningful technical and business value.
We will also examine current industry trends, emerging applications and practical decision points for selecting cyclodextrins, suppliers and development partners.
Designed for R&D, business development and commercial professionals, the session will help you: – identify promising cyclodextrin applications across different therapeutic modalities; – distinguish realistic opportunities from overpromising claims; – understand the key technical and commercial questions to ask suppliers and CDMOs; – prepare more effectively for scientific and partnering discussions at CPHI.
Expect a pragmatic, data-driven session covering a little bit of everything—from formulation science to commercial products and future opportunities. Bring your own use cases and questions.
The session will be interactive, practical and focused on insights you can take directly into your next development project or CPHI meeting.
Continue the conversation at CarboHyde’s booth 8S83 for deeper dives into your projects and what’s next in CD-enabled therapies.
Great recognition for the GENEGUT project and our cyclodextrin science was received recently:
“Dear EU-funded innovator(s), We are writing to you as you are an official contact person for your organisation’s participation in the GENEGUT project funded by the European Commission under Horizon Europe.
We are delighted to inform you that one of the innovations developed in the project has been analysed by the European Commission’s Innovation Radar.
Details of this innovation, and how it was categorised by the analysis, are as follows:
Innovation Title: Scaling-up Environmentally-Friendly Processes for ad-hoc designed RNA-driven vehicles;
Market Maturity of the Innovation: Business Ready
Market Creation Potential of the innovation: Addresses needs of existing markets
In this analysis Innovation Radar also identified the following project partner(s) – including your organisation – in the project as a ‘Key Innovator’ in the development of this innovation: CarboHyde ZARTKORUEN MUKODO RESZVENYTARSASAG
In the near future we will publish the above information about this innovation on the European Commission’s Innovation Radar platform.”
So stay tuned, as soon you can read more about our RNA delivery platform on the EU’s portal too.
You may ask, where do cyclodextrin experts learn new tricks?
Of course, from other experts!
That is why we were extremely, grateful when Carmen Popescu from Roquette offered to give us a 2-day in person training. Even more so as Mohammad Qadir joined too.
So we gathered a small team of students and colleagues and are now bathing in cyclodextrin formulations.
1. Safe excretion of 7KC (7-keto-cholesterol), a core driver of plaque associated with heart disease, stroke, inflammation, and age-related diseases, in humans suggests medicine could move beyond slowing heart disease to disease-modifying plaque reversal
2. First candidate from Cyclarity’s AI Platform reinforces promise of next-generation cyclodextrins to reverse disease and protect against future accumulation of harmful molecules and aging pathologies
Cyclarity’s UDP-003 binds directly to 7KC, the root cause of plaque buildup, then facilitates urinary excretion of it. Much like removing rust from metal, this approach directly targets a key source of damage within plaque with the goal of reversing and preventing atherosclerosis, a primary underlying cause of cardiovascular disease, and does so locally within the plaque to reduce risks of unintended systemic effects.
Plaque reversal is significant because research suggests that even a 1% reduction in coronary plaque burden has been associated with up to 25% lower risk of major cardiovascular events, such as heart attack or stroke.
In parallel, they are preparing for the launch of our Phase 2 trial, expected to kick off in early 2027.
Cyclarity Therapeutics is a clinical stage biopharmaceutical company engineering cyclodextrin molecules into simple, scalable, and affordable therapies that bind and remove toxic targets to address root causes of age-related disease.
Together we explored the role, chemistry and biology of defensins, of course with the help of cyclodextrins, particularly succinylated-BCD polymer.
Defensins are a large and ancient family of host–defence peptides present across vertebrates, invertebrates, and plants, where they play a crucial role in innate immunity.
Here, we made a photoresponsive β-cyclodextrin branched polymer, where excitation of the Poly-βCD1 with visible blue light results in the generation of nitric oxide.
The negligible cytotoxic action of DOX, used well below the therapeutic doses, alone or in combination with the polymer in the dark, is enhanced in both cell lines under light irradiation exclusively when the drug is combined with Poly-βCD1 as a result of the combined action of NO.
Here, we made a photoresponsive β-cyclodextrin branched polymer, where excitation of the Poly-βCD1 with visible blue light results in the generation of nitric oxide.
The negligible cytotoxic action of DOX, used well below the therapeutic doses, alone or in combination with the polymer in the dark, is enhanced in both cell lines under light irradiation exclusively when the drug is combined with Poly-βCD1 as a result of the combined action of NO.
Using CDs for wound healing has been in the spotlight for a long time, many applications and promising prototypes were developed, yet none reached the market.
This may change with the innovation of Jun Li at National University of Singapore who made a smart multifunctional ROS-responsive supramolecular hydrogel.
The polymer is dynamically crosslinked by inclusion complexes of β-cyclodextrin (βCD) and ferrocene (Fc).
This hydrogel facilitates the on-demand release of interleukin-4 (IL-4) while exhibiting intrinsic antibacterial properties.
The system subsequently reprograms macrophages from the proinflammatory M1 phenotype to the anti‒inflammatory M2 phenotype, thereby addressing immune dysregulation in diabetic wounds.
The composition significantly enhanced wound closure, collagen density, and angiogenesis while reducing proinflammatory cytokines (IL-6 and TNF-α) and increasing anti‒inflammatory cytokine IL-10 levels.
